<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330846</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOCIR</org_study_id>
    <nct_id>NCT04330846</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Chron's Disease.</brief_title>
  <acronym>ENDOCIR</acronym>
  <official_title>Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Crohn's Disease. Endoscopic Treatment (Self-expanding Metal Prosthesis/Ballon Dilation) vc Surgical Resection (ENDOCIR STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stenosis is one of the most frequent complications in patients with Crohn's disease (CD),
      causing greater morbidity and increasing the probability of repeated surgery and short bowel
      syndrome (1-3). Endoscopic balloon dilation (EBD) is clearly the treatment of choice for
      short stenoses located at the anastomosis of previous surgeries (4-6). However, there is no
      scientific evidence for determining the most appropriate treatment for de novo stenosis less
      than 10 cm in length (surgical versus endoscopic treatment), both in terms of efficacy and
      complications. Neither has it been established which of these two approaches has a greater
      impact on the quality of life of patients and on costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In many cases, a surgical approach allows for the removal of the entire inflamed intestine.
      However, the percentage of post-surgical recurrence per year after surgery is 80-85% (7),
      decreasing to 40% in patients who begin preventive immunosuppressive treatment in the
      immediate post-surgery period (8). This means that more than 40% of patients will require
      combined immunosuppression to keep CD under control one year after surgery. Endoscopic
      treatment does not remove the affected intestine. However, it has a long-term therapeutic
      efficacy of 50-60% with a very low percentage of complications (4-6%).

      A large number of studies have shown that patients' quality of life improves when CD is
      properly controlled, either through medical or surgical treatment (9). However, there are no
      studies evaluating the quality of life of patients after endoscopic treatment.

      Neither are there comparative studies of the costs of the two procedures. However, a recent
      study comparing the cost of 38 endoscopic procedures with their surgical equivalent suggested
      that, in most cases, the cost of endoscopic treatment is four times lower (10).

      The European Crohn's and Colitis Organization (ECCO) guidelines on the management of de novo
      stenosis in patients with CD recommend surgery as the first option, based on expert opinion
      (Level of Evidence 4), although there are no studies comparing the two treatment modalities
      (11,12).

      A Spanish multicenter study coordinated by researchers involved in the present project
      (Andujar X, et al)(13), which included the largest published series of endoscopic treatment
      with dilation in patients with CD to date, shows that therapeutic success with EBD in de novo
      stenoses is achieved in a large percentage of cases, with results similar to those obtained
      in post-surgical stenoses (73% vs 84%).

      In addition, CD stenoses can be treated effectively with self-expanding metal stents (SEMS),
      and it has been suggested that these may be particularly indicated in patients who are
      refractory to balloon dilation, including both de novo and anastomotic stenosis patients
      (14-17). Therefore, in order to compare the efficacy of these two endoscopic treatments, the
      PROTDILAT study (IP: C Loras. Project FIS nº Pl13/01226 and Clinical Trials. Gov nº
      NCT02395354) was designed, and is currently in the final manuscript writing phase (100
      patients included). The final results (Andújar X, UEGW 2019)(18) confirm that both procedures
      are effective and safe in the treatment of both post-surgical and de novo stenosis, while
      showing the therapeutic superiority of EBD over SEMS when the results are evaluated globally
      (80.5 vs 51.3 %; primary end point). However, this difference is not observed in the
      subanalysis of patients with stenosis ≥4 cm (LBD: 66.7% vs PMA: 63.6%). Therefore, SEMS may
      have a role to play in those ≥4 cm stenoses in which EBD has proven to be less efficacious.

      This work has been conceived as an exploratory proof of concept study, given that there are
      currently no studies comparing surgical and endoscopic approaches and it is therefore
      difficult to calculate the adequate sample size.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life of patients</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>Percentage of patients with an increase of more than 30 points in the Inflammatory Bowel Disease Questionnaire (IBDQ-32) quality of life index. The higher the better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clinical recurrence</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>Percentage of patients with clinical recurrence (scale of obstructive symptoms 0-6) and costs. The lower the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of complications</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>Percentage of complications and costs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>EBD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-procedural admission in the Short Stay Unit (SSU).
Superficial sedation by endoscopist or anesthesiologist depending on the center.
Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion.
A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation.
Dilation failure will be considered if &gt; 2 dilations are required.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEMS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-procedural admission in the Short Stay Unit (SSU).
Superficial sedation by endoscopist or anesthesiologist depending on the center.
Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist
Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion.
Removal time of the prosthesis 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>The length of the stenosis will determine the endoscopic technique of choice. In cases where the stenosis is &gt; 4 cm, treatment will be carried out with SEMS, while EBD will be performed if the stenosis is ≤ 4 cm.</description>
    <arm_group_label>EBD group</arm_group_label>
    <arm_group_label>SEMS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years of age.

          -  Crohn's disease with predominantly de novo fibrotic stenosis* confirmed by endoscopic
             and radiological tests, accessible by endoscopy (colonoscopy).

          -  Patients with known stenosis previously treated with stenting and/or dilation
             performed over one year before the date of inclusion.

          -  Symptomatology of intestinal occlusion-subocclusion.

          -  Refractoriness to conventional medical treatment (non-response to the usual
             accelerated step-up therapeutic approach).

          -  Stenosis length &lt; 10 cm.

          -  Maximum of 2 stenoses.

          -  Informed consent from patient.

        Exclusion Criteria:

          -  No informed consent from the patient.

          -  Complicated stenosis with abscess, fistula or significant activity associated with CD
             not limited to the area of the stenosis.

          -  Patients with known stenosis previously treated with stenting and/or dilation
             performed &lt; 1 year before the date of inclusion.

          -  Pregnancy or lactation.

          -  Any clinical situation that prevents the performance of endoscopy or surgery.

          -  Stenosis not accessible by endoscopy.

          -  Asymptomatic patient.

          -  Stenosis length ≥ 10 cm.

          -  Presents with &gt; 2 stenoses.

          -  Severe coagulation disorders (platelets &lt; 70000; INR &gt; 1.8).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carme Loras</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Casas</last_name>
    <phone>635 899 553</phone>
    <email>secretariacientifica2@geteccu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugeni Domènech</last_name>
    <email>eugenidomenech@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Althaia, xarxa assistencial universitaria de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cáceres</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Inca</name>
      <address>
        <city>Inca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785-94. doi: 10.1053/j.gastro.2011.01.055.</citation>
    <PMID>21530745</PMID>
  </reference>
  <reference>
    <citation>Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I; IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8.</citation>
    <PMID>18054751</PMID>
  </reference>
  <reference>
    <citation>Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb;105(2):289-97. doi: 10.1038/ajg.2009.579. Epub 2009 Oct 27. Review.</citation>
    <PMID>19861953</PMID>
  </reference>
  <reference>
    <citation>Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S. Systematic review: Endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1457-64. Epub 2007 Sep 28. Review.</citation>
    <PMID>17903236</PMID>
  </reference>
  <reference>
    <citation>Morar PS, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D, Abercrombie J, Ragunath K, Sanders DS, Arnott I, Wilson G, Bloom S, Arebi N; Crohn's Stricture Study (CroSS) Group. Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn's disease strictures. Aliment Pharmacol Ther. 2015 Nov;42(10):1137-48. doi: 10.1111/apt.13388. Epub 2015 Sep 11. Review.</citation>
    <PMID>26358739</PMID>
  </reference>
  <reference>
    <citation>Navaneethan U, Lourdusamy V, Njei B, Shen B. Endoscopic balloon dilation in the management of strictures in Crohn's disease: a systematic review and meta-analysis of non-randomized trials. Surg Endosc. 2016 Dec;30(12):5434-5443. Epub 2016 Apr 28. Review.</citation>
    <PMID>27126619</PMID>
  </reference>
  <reference>
    <citation>Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990 Oct;99(4):956-63.</citation>
    <PMID>2394349</PMID>
  </reference>
  <reference>
    <citation>Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009 Aug;104(8):2089-96. doi: 10.1038/ajg.2009.301. Epub 2009 Jun 30. Review.</citation>
    <PMID>19568226</PMID>
  </reference>
  <reference>
    <citation>Loras C, Mayor V, Fernández-Bañares F, Esteve M. Study of the standard direct costs of various techniques of advanced endoscopy. Comparison with surgical alternatives. Dig Liver Dis. 2018 Jul;50(7):689-697. doi: 10.1016/j.dld.2018.03.002. Epub 2018 Mar 12.</citation>
    <PMID>29610018</PMID>
  </reference>
  <reference>
    <citation>Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2015 May;21(5):1187-94. doi: 10.1097/MIB.0000000000000271. Review.</citation>
    <PMID>25895008</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, Adamina M, Ardizzone S, Buskens CJ, Sebastian S, Laureti S, Sampietro GM, Vucelic B, van der Woude CJ, Barreiro-de Acosta M, Maaser C, Portela F, Vavricka SR, Gomollón F; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017 Feb;11(2):135-149. doi: 10.1093/ecco-jcc/jjw169. Epub 2016 Sep 22.</citation>
    <PMID>27660342</PMID>
  </reference>
  <reference>
    <citation>Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, de Buck van Overstraeten A, Burke JP, Buskens CJ, Colombo F, Dias JA, Eliakim R, Elosua T, Gecim IE, Kolacek S, Kierkus J, Kolho KL, Lefevre JH, Millan M, Panis Y, Pinkney T, Russell RK, Shwaartz C, Vaizey C, Yassin N, D'Hoore A. ECCO-ESCP Consensus on Surgery for Crohn's Disease. J Crohns Colitis. 2018 Jan 5;12(1):1-16. doi: 10.1093/ecco-jcc/jjx061.</citation>
    <PMID>28498901</PMID>
  </reference>
  <reference>
    <citation>Andújar X, Loras C, González B, Socarras M, Sanchiz V, Boscà M, Domenech E, Calafat M, Rodríguez E, Sicilia B, Calvet X, Barrio J, Guardiola J, Iglesias E, Casanova MJ, Ber Y, Monfort D, López-Sanromán A, Rodríguez-Lago I, Bujanda L, Márquez L, Martín-Arranz MD, Zabana Y, Fernández-Bañares F, Esteve M; ENEIDA registry of GETECCU. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surg Endosc. 2020 Mar;34(3):1112-1122. doi: 10.1007/s00464-019-06858-z. Epub 2019 May 29. Erratum in: Surg Endosc. 2019 Jun 18;:.</citation>
    <PMID>31144122</PMID>
  </reference>
  <reference>
    <citation>Attar A, Maunoury V, Vahedi K, Vernier-Massouille G, Vida S, Bulois P, Colombel JF, Bouhnik Y; GETAID. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis. 2012 Oct;18(10):1849-54. doi: 10.1002/ibd.22844. Epub 2011 Dec 11.</citation>
    <PMID>22161935</PMID>
  </reference>
  <reference>
    <citation>Levine RA, Wasvary H, Kadro O. Endoprosthetic management of refractory ileocolonic anastomotic strictures after resection for Crohn's disease: report of nine-year follow-up and review of the literature. Inflamm Bowel Dis. 2012 Mar;18(3):506-12. doi: 10.1002/ibd.21739. Epub 2011 May 3. Review.</citation>
    <PMID>21542067</PMID>
  </reference>
  <reference>
    <citation>Loras C, Pérez-Roldan F, Gornals JB, Barrio J, Igea F, González-Huix F, González-Carro P, Pérez-Miranda M, Espinós JC, Fernández-Bañares F, Esteve M. Endoscopic treatment with self-expanding metal stents for Crohn’s disease strictures. Aliment Pharmacol Ther. 2012 Nov;36(9):833-9.</citation>
    <PMID>22966851</PMID>
  </reference>
  <reference>
    <citation>Loras Alastruey C, Andújar Murcia X, Esteve Comas M. The role of stents in the treatment of Crohn's disease strictures. Endosc Int Open. 2016 Mar;4(3):E301-8. doi: 10.1055/s-0042-101786. Review.</citation>
    <PMID>27014743</PMID>
  </reference>
  <reference>
    <citation>Multicenter prospective randomized study to compare endoscopic treatment of strictures in crohn´s disease: self-expanding metal stents vs endoscopic balloon dilation. Protdilat study. Andujar X, Loras Alastruey C, Gornals J.B, Guardiola J., Sanchiz V., Bosca M., Brullet E., Sicília Aladrén B., Naranjo Rodríguez A., Martín-Arranz M.D., Dueñas-Sadornil C., Foruny J.R., Barrio Andrés J., Monfort Miquel D., Busquets Casals D., Pineda J.R., Pérez-Roldán F., Pons Beltrán V., González-Huix Lladó F., Sainz E., Gonzalez B.9,, Reyes Moreno J., Fernández-Bañares F.9,, Esteve M. 27rd United European Gastroenterology Week (UEGW). Barcelona 2019. UNITED EUROPEAN GASTROENTEROLOGY Barcelona 22- 24 October 2019.</citation>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>crohn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

